A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
The Market for Biosimilars Is Funky. The Industry Thinks PBMs Are To Blame
Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]
Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, or PBMs, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
Humira lleva 20 años disfrutando de una exclusividad muy cara en el país. Sus competidores podrían ahorrarle al sistema sanitario $9,000 millones.
Por qué los CDC recomiendan el nuevo refuerzo contra covid para todos
El Comité Asesor sobre Prácticas de Inmunización de los CDC votó 13-1 a favor de la moción después de meses de debate sobre si limitar los refuerzos a grupos de alto riesgo.
Why the CDC Has Recommended New Covid Boosters for All
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it’s time for new boosters — and not only for those at highest risk of serious disease. Here are seven things you need to know.
A pesar de las amplias recomendaciones para el refuerzo anticovid actualizado publicadas el otoño pasado, sólo el 17% de la población la recibió, y alrededor del 43% de las personas de 65 años o más.
Pfizer and Moderna Are Pushing the New Covid Booster. Should You Get It? The CDC Is About to Decide.
Chances are, if you aren’t older, chronically ill, or obese, you don’t need a forthcoming covid vaccine to stay out of the hospital. But it probably wouldn’t hurt.
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.
What You Need to Know About the Drug Price Fight in Those TV Ads
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.
El cisplatino y el carboplatino son algunos de los medicamentos que escasean, así como otros 12 contra el cáncer, pastillas para el trastorno por déficit de atención con hiperactividad, anticoagulantes y antibióticos.
Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
La Comisión Federal de Comercio está actuando contra las empresas farmacéuticas y los intermediarios del sector, como parte de la campaña de la administración Biden para reducir los precios de los medicamentos en las farmacias.
PBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention
Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
La empresa farmacéutica que prosperó sin crear ni un solo medicamento
Aunque Horizon afirma que ahora tiene 20 fármacos en desarrollo, en sus 15 años de existencia aún no ha obtenido la licencia de un producto de su creación.
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
